Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CIITA encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. Additionally we are shipping Class II, Major Histocompatibility Complex, Transactivator Proteins (3) and many more products for this protein.
Showing 10 out of 50 products:
Pig (Porcine) Polyclonal CIITA Primary Antibody for WB - ABIN97339
Koues, Dudley, Mehta, Greer: The 19S proteasome positively regulates histone methylation at cytokine inducible genes. in Biochimica et biophysica acta 2009
Human Polyclonal CIITA Primary Antibody for IHC (p), WB - ABIN4886541
Sun, Huang, Yu, Zhang, Xu, Zhang, Li, Dong, Guo, Wang: Autoregulatory loop between TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma modulates proliferation and differentiation. in Cell death & disease 2016
study found that CIITA exerts a highly restricted control over only the MHCII, H2-DO and H2-DM genes, in DC1 and DC2 (show OSTC Antibodies) cDC (show CDK1 Antibodies) subsets, but not over other proposed targets
Decreasing CIITA expression in allogeneic MSCs abolished MHC II induction during myogenic differentiation and prevented immunorejection of these cells from the infarcted myocardium, which enhanced beneficial functional effects of MSC (show MSC Antibodies) implantation on myocardial repair.
M. tuberculosis EsxL inhibits antigen presentation by enhancing H3K9me2/3 at the CIITA promoter, thereby repressing its expression through NO and p38 MAPK (show MAPK14 Antibodies) activation
this study shows that genetic polymorphisms in the type I promoter of C2ta regulate MHC-II expression and T-cell responses but do not necessarily have a strong impact on autoimmune diseases
CIITA interacted with and recruited PRMT5 to the MHC II promoter and mediated the synergy between PRMT5 and ASH2/WDR5 to activate MHC II transcription
NLRC5 (show NLRC5 Antibodies) and CIITA thus emerge as paradigms for a novel class of transcriptional regulators dedicated for transactivating extremely few, phylogenetically related genes.
Data suggest that class II transactivator CIITA expression is likely mediated in hematopoietic cells by common elements with promoter accessibility having a part in promoter choice.
Transfection of CIITA in poorly immunogenic PDA cells resulted in increased expression levels of the MHC class II molecule. CIITA-tumor cells were rejected in 80% to 100% of injected mice.
IFN-gamma exerts a critical anti-inflammatory function in the intestine which protects against colitis by inducing MHCII expression on intestinal epithelial cells.
tumor cell lines with a defective expression of CIITA transcripts lack MHC class II expression
CIITA expression is higher when carried by FP single recombinants than when combined with FPgp or FPenv constructs and can induce HLA-DR cell surface expression. However, in-vivo experiments did not show any significant increase in the humoral response. As CIITA already proved to elicit immunogenicity by improving antigen presentation, further in-vivo experiments should be performed to increase the immune responses
Therefore, our data identify HIC1 (show HIC1 Antibodies) as a novel factor involved in B cell differentiation acting as an epigenetic repressor of CIITA transcription.
B. abortus lipoproteins via IL-6 (show IL6 Antibodies) inhibit the expression of IFN regulatory factor 1 (IRF-1 (show IRF1 Antibodies)), a critical regulatory transcription factor for CIITA induction.
Brazilian Amerindian ancestry compared to Asian, European, and African Genomes.SNPs within or proximal to CIITA (rs6498115), SMC6 (show SMC6 Antibodies) (rs1834619), and KLHL29 (rs2288697) were most differentiated in the Amerindian-specific branch. SNPs in ADAMTS9 (show ADAMTS9 Antibodies) (rs7631391), DOCK2 (show DOCK2 Antibodies) (rs77594147), SLC28A1 (show SLC28A1 Antibodies) (rs28649017), ARHGAP5 (show ARHGAP5 Antibodies) (rs7151991), and CIITA (rs45601437) in the Asian comparison.
CLPTM1L (show CLPTM1L Antibodies) and TERT (show TERT Antibodies) have been implicated in cancers, and CIITA is considered as the "master control factor" for the expression of NPC (show NPC1 Antibodies)-associated MHC class II (show HLA-DPA1 Antibodies) genes. These suggested that both SNPs might be functional. Altogether, our findings expand our understanding of the genetic contribution to NPC (show NPC1 Antibodies) risk and provide novel biological insights into NPC (show NPC1 Antibodies) pathogenesis.
When mouse pDCs and CAL-1 cells were stimulated by GM-CSF, mRNA levels of PU.1, pIII-driven CIITA, total CIITA, MHC class II, and the amount of PU.1 binding to pIII were significantly increased
the MHC2TA -168 A/G polymorphism is not associated with susceptibility to rheumatoid arthritis in Caucasians [meta-analysis]
Observed no association between the MHC2TA or FCRL3 (show FCRL3 Antibodies) SNPs and rheumatoid arthritis in Mexican patients.
CIITA acts as a general restriction factor against HIV-1 not only in T cells but also in myeloid cells.
This gene encodes a protein with an acidic transcriptional activation domain, 4 LRRs (leucine-rich repeats) and a GTP binding domain. The protein is located in the nucleus and acts as a positive regulator of class II major histocompatibility complex gene transcription, and is referred to as the 'master control factor' for the expression of these genes. The protein also binds GTP and uses GTP binding to facilitate its own transport into the nucleus. Once in the nucleus it does not bind DNA but rather uses an intrinsic acetyltransferase (AT) activity to act in a coactivator-like fashion. Mutations in this gene have been associated with bare lymphocyte syndrome type II (also known as hereditary MHC class II deficiency or HLA class II-deficient combined immunodeficiency), increased susceptibility to rheumatoid arthritis, multiple sclerosis, and possibly myocardial infarction.
class II, major histocompatibility complex, transactivator
, class II transactivator-like
, class II transactivator
, MHC class II transactivator-like
, MHC class II transactivator
, MHC class II transactivator type III
, NLR family, acid domain containing
, nucleotide-binding oligomerization domain, leucine rich repeat and acid domain containing
, MHC class II transactivator type IV